Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation
Open Access
- 5 March 2003
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 17 (8), 1-18
- https://doi.org/10.1096/fj.02-0799fje
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder with no effective protective treatment, characterized by a massive degeneration of dopaminergic neurons in the substantia nigra (SNpc) ...Keywords
Funding Information
- National Institute of Mental Health
- National Institutes of Health
This publication has 46 references indexed in Scilit:
- Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's diseaseThe FASEB Journal, 2002
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microgliaGlia, 2002
- Alpha-synuclein and neurodegenerative diseasesNature Reviews Neuroscience, 2001
- Immunobiology of vasoactive intestinal peptide (VIP)Immunology Today, 2000
- Regulation of the Heparan Sulfate Proteoglycan, Perlecan, by Injury and Interleukin‐1αJournal of Neurochemistry, 1999
- Development of High Affinity Selective VIP1 Receptor AgonistsPeptides, 1997
- Microglia: a sensor for pathological events in the CNSTrends in Neurosciences, 1996
- Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons In VivoEuropean Journal of Neuroscience, 1995
- Role of mitochondria in the etiology and pathogenesis of Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1995
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990